140 related articles for article (PubMed ID: 16704208)
1. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
Chuang KH; Cheng CM; Roffler SR; Lu YL; Lin SR; Wang JY; Tzou WS; Su YC; Chen BM; Cheng TL
Bioconjug Chem; 2006; 17(3):707-14. PubMed ID: 16704208
[TBL] [Abstract][Full Text] [Related]
2. Hapten-directed targeting to single-chain antibody receptors.
Cheng TL; Liao KW; Tzou SC; Cheng CM; Chen BM; Roffler SR
Cancer Gene Ther; 2004 May; 11(5):380-8. PubMed ID: 15044963
[TBL] [Abstract][Full Text] [Related]
3. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.
Cheng TL; Wu PY; Wu MF; Chern JW; Roffler SR
Bioconjug Chem; 1999; 10(3):520-8. PubMed ID: 10346886
[TBL] [Abstract][Full Text] [Related]
4. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.
Cheng TL; Wei SL; Chen BM; Chern JW; Wu MF; Liu PW; Roffler SR
Br J Cancer; 1999 Mar; 79(9-10):1378-85. PubMed ID: 10188879
[TBL] [Abstract][Full Text] [Related]
5. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.
Cheng TL; Chen BM; Chan LY; Wu PY; Chern JW; Roffler SR
Cancer Immunol Immunother; 1997 Aug; 44(6):305-15. PubMed ID: 9298932
[TBL] [Abstract][Full Text] [Related]
6. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
7. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting prodrug-activating bacteria for cancer therapy.
Cheng CM; Lu YL; Chuang KH; Hung WC; Shiea J; Su YC; Kao CH; Chen BM; Roffler S; Cheng TL
Cancer Gene Ther; 2008 Jun; 15(6):393-401. PubMed ID: 18369382
[TBL] [Abstract][Full Text] [Related]
9. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes.
Chen KC; Cheng TL; Leu YL; Prijovich ZM; Chuang CH; Chen BM; Roffler SR
Cancer Gene Ther; 2007 Feb; 14(2):187-200. PubMed ID: 16977328
[TBL] [Abstract][Full Text] [Related]
10. Hapten-derivatized nanoparticle targeting and imaging of gene expression by multimodality imaging systems.
Cheng CM; Chu PY; Chuang KH; Roffler SR; Kao CH; Tseng WL; Shiea J; Chang WD; Su YC; Chen BM; Wang YM; Cheng TL
Cancer Gene Ther; 2009 Jan; 16(1):83-90. PubMed ID: 18802451
[TBL] [Abstract][Full Text] [Related]
11. Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase.
Su YC; Chuang KH; Wang YM; Cheng CM; Lin SR; Wang JY; Hwang JJ; Chen BM; Chen KC; Roffler S; Cheng TL
Gene Ther; 2007 Apr; 14(7):565-74. PubMed ID: 17235292
[TBL] [Abstract][Full Text] [Related]
12. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.
Cheng TL; Chen BM; Chern JW; Wu MF; Roffler SR
Bioconjug Chem; 2000; 11(2):258-66. PubMed ID: 10725103
[TBL] [Abstract][Full Text] [Related]
13. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation.
Harvill ET; Fleming JM; Morrison SL
J Immunol; 1996 Oct; 157(7):3165-70. PubMed ID: 8816429
[TBL] [Abstract][Full Text] [Related]
14. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats.
Chen BM; Chan LY; Wang SM; Wu MF; Chern JW; Roffler SR
Int J Cancer; 1997 Nov; 73(3):392-402. PubMed ID: 9359487
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
16. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
[TBL] [Abstract][Full Text] [Related]
18. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
[TBL] [Abstract][Full Text] [Related]
19. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an antineoplastic glucuronide prodrug.
Cheng TL; Chou WC; Chen BM; Chern JW; Roffler SR
Biochem Pharmacol; 1999 Jul; 58(2):325-8. PubMed ID: 10423174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
